Investment of £226 million to help UK to 'lead the world in fighting cancer'

30 November 2016

Cancer Research UK (CRUK), the world’s leading charity researching the disease, has made its largest ever investment into its network of centers across the country.

Some £190 million ($237 million) has been committed to 13 CRUK centers over the next five years, while the charity and the UK’s Department of Health are investing a further £36 million into 18 Experimental Cancer Medicine Centers (ECMCs) for adult patients and also a network sites for children.

"This is particularly important for hard-to-treat cancers like pancreatic, oesophageal, lung and brain tumours"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK